RRM2
ENSG00000171848
Target class
Enzyme
Chromosome
2
Approved drugs
5
Clinical candidates (approved and in development)
7
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Other names
- FLJ25102
- Target name
- RRM2
- Gene name
- Ribonucleotide reductase regulatory subunit M2
- Gene symbol
- RRM2
- Previous gene symbols
- C2orf48
- Protein name
- Ribonucleoside-diphosphate reductase subunit M2 (EC 1.17.4.1) (Ribonucleotide reductase small chain) (Ribonucleotide reductase small subunit)
- Gene biotype
- Protein coding
- Gene family
- Ribonucleotide reductase subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 174.48
- Tissue specificity (Gini)
- 0.9
- Tissue specificity (tau)
- 0.987
- KEGG gene identifiers
- hsa:6241
- Protein interaction confidence
- 0.843069
- Protein interaction partners
- 130
- R-HSA-499943
- R-HSA-69205
- R-HSA-8953750
- End position
- 10211725
- Start position
- 10120698
- Chromosome
- 2
- Strand
- Forward
- Cytoplasm . Nucleus . Note=Localized to the cytoplasm in S phase cells. May localize to the nucleus in G2 phase cells. .
- Cytosol
- Nucleoplasm
Publication evidence
- PubMed 22632967
- Tissue specificity (tau)
- 0.986674
- Expression inequality (Gini)
- 0.899917
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 174.48
- Cells - Cultured fibroblasts
- 39.77
- Esophagus - Mucosa
- 22.89
- Spleen
- 11.1
- Small Intestine - Terminal Ileum
- 8.18
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes174.48
- Cells - Cultured fibroblasts39.77
- Esophagus - Mucosa22.89
- Spleen11.1
- Small Intestine - Terminal Ileum8.18
- Testis6.59
- Vagina5.51
- Colon - Transverse4.74
- Whole Blood3.27
- Skin - Not Sun Exposed (Suprapubic)2.61
- Lung2.41
- Skin - Sun Exposed (Lower leg)2.38
- Minor Salivary Gland1.24
- Stomach1.23
- Adrenal Gland1.01
- Artery - Coronary0.82
- Artery - Aorta0.66
- Adipose - Visceral (Omentum)0.64
- Cervix - Endocervix0.63
- Adipose - Subcutaneous0.55
- Liver0.54
- Bladder0.52
- Kidney - Medulla0.49
- Prostate0.47
- Breast - Mammary Tissue0.45
And 29 more, listed on the interactive page.
- GO:0006281
- GO:0009185
- GO:0009265
- GO:1900087
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
Molecular functions
- GO:0005515
Related records
Trials (4,955)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Drugs (10)
- Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Fludarabine phosphate Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gallium nitrate Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gemcitabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor
- GTI-2040 Ribonucleotide reductase small subunit mRNA antisense inhibitor
- Hydroxyurea Ribonucleoside-diphosphate reductase RR1 inhibitor
- Motexafin gadolinium Ribonucleoside-diphosphate reductase RR1 inhibitor
- Tezacitabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Tezacitabine anhydrous Ribonucleoside-diphosphate reductase RR1 inhibitor